This is a double blind, Randomized Clinical Trial (RCT) that patients diagnosed with migraine (men and women within an age range of 18-65), according to IHS diagnostic criteria, with more than 6 attacks per month and taking no migraine prophylaxis medications, after obtaining informed consent, and explain the possible side effects of medication are included in randomized blocks under treatment with Memantine, 10mg per day, or Sodium Valporate (Depakine), 500mg per day, and are investigated 3 months after medication. Neither the patients nor the physicians are aware of the type of medication used in each group. The primary outcome measure is the average number of attacks in each month. Secondary outcome measures are: Average number of days with migraine headaches per month, The mean pain intensity from 0-3 before taking an analgesic, Number and type of medications used per attack, Number of respondents (50% or more reduction in rate of attacks, 50% or more reduction in the number of days with migraine headaches), Side effects and Quality of life. SF-12, MIDAS and HADS is filled at the beginning and the end of the study for evaluating patients’ performance. In the case of no improvement in patient’s headache or Exacerbation of it , standard migraine prophylaxis medication will be applied and at the end it will be decoded.